COST-EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS FOLFIRI VERSUS FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER: A UK PERSPECTIVE

被引：0
|
作者：
Gyldmark, M. [1 ]
Aultman, R. [1 ]
Siebert, U. [2 ]
Sabate, E. [3 ]
机构：
[1] F Hoffmann La Roche Ltd, Basel, Switzerland
[2] UMIT Univ Hlth Sci Med Informat & Technol, Hall In Tirol, Austria
[3] F Hoffmann La Roche Pharmaceut AG, Basel, Switzerland
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)73306-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A49 / A49
页数：1
相关论文
共 50 条
  • [1] Clinical and Cost Effectiveness of Bevacizumab plus FOLFIRI Combination Versus FOLFIRI Alone as First-Line Treatment of Metastatic Colorectal Cancer in South Korea
    Lee, Eui-Kyung
    Revil, Cedric
    Ngoh, Charles A.
    Lister, Johanna
    Kwon, Jeong-Mi
    Park, Mee-Hye
    Park, Seok-Jin
    Park, Young-Suk
    Shin, Sang-Joon
    Lee, Myung-Ah
    Lee, Nam-Su
    Zang, Dae-Young
    Bae, Eun-Jin
    Kang, Mi-Jeong
    CLINICAL THERAPEUTICS, 2012, 34 (06) : 1408 - 1419
  • [2] Cost-effectiveness of cetuximab plus FOLFIRI versus bevacizumab plus FOLFIRI in the first-line treatment of RAS wild-type metastatic colorectal cancer in China.
    Van Oostrum, Ilse
    Hu Yannan
    Yuan Zijiao
    Schlichting, Michael
    Tao Libo
    Pescott, Chris P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [3] COST EFFECTIVENESS OF BEVACIZUMAB PLUS FOLFIRI VERSUS FOLFIRI IN TREATMENT OF ADVANCED METASTATIC COLORECTAL CANCER IN THE REPUBLIC OF KOREA
    Lee, Eui-Kyung
    Revil, Cedric
    Ngoh, Charles
    Lister, Johanna
    Kwon, Jeongmi
    Park, Meehye
    Park, Seokjin
    Park, Youngsuk
    Shin, Sangjoon
    Lee, Myungah
    Lee, Namsu
    Zang, Dae Young
    Bae, Eunjin
    Kang, Mijeong
    ANNALS OF ONCOLOGY, 2011, 22 : v125 - v125
  • [4] Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment
    Huang, Ching-Wen
    Yeh, Yung-Sung
    Ma, Cheng-Jen
    Tsai, Hsiang-Lin
    Chen, Chao-Wen
    Huang, Ming-Yii
    Lu, Chien-Yu
    Wu, Jeng-Yih
    Wang, Jaw Yuan
    CHEMOTHERAPY, 2017, 62 (01) : 80 - 84
  • [5] EFFECTIVENESS AND SAFETY OF FIRST-LINE BEVACIZUMAB PLUS FOLFIRI IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Pinto, Ana Catarina
    Teixeira, Margarida
    Bonito, Nuno
    Jacinto, Paula
    Ribeiro, Joao
    Gervasio, Helena
    ANNALS OF ONCOLOGY, 2011, 22 : v98 - v98
  • [6] A COST AND OUTCOMES ANALYSIS OF BEVACIZUMAB PLUS FOLFIRI VERSUS CETUXIMAB PLUS FOLFIRI FOR THE TREATMENT OF FIRST-LINE METASTATIC COLORRECTAL CANCER PATIENTS FROM THE BRAZILIAN PRIVATE PAYER PERSPECTIVE
    Caponero, R.
    Santos, E. A., V
    Buschinelli, C. T.
    Ferracini, M.
    Ngoh, C. A.
    VALUE IN HEALTH, 2011, 14 (07) : A446 - A446
  • [7] A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ahmet, Bilici
    Uygun, Kazim
    Kaya, Serap
    Ustaalioglu, Bala Basak Oven
    Yildiz, Ramazan
    Temiz, Suleyman
    Seker, Mesut
    Aksu, Gorkem
    Cabuk, Devrim
    Gumus, Mahmut
    ANNALS OF ONCOLOGY, 2012, 23 : 98 - 99
  • [8] The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer
    不详
    CLINICAL COLORECTAL CANCER, 2007, 6 (09) : 621 - 624
  • [9] FOLFIRI VS FOLFIRI plus BEVACIZUMAB IN FIRST-LINE THERAPY OF METASTATIC COLORECTAL CANCER: RETROSPECTIVE ANALYSIS OF 81 PATIENTS IN OUR INSTITUTION
    Rakusic, Z.
    Jajac, L.
    Juretic, A.
    Bisof, V.
    Misir-Krpan, A.
    Santek, F.
    Basic-Koretic, M.
    Plestina, S.
    ANNALS OF ONCOLOGY, 2010, 21 : 217 - 217
  • [10] Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work
    Gerard Harty
    James Jarrett
    Mireia Jofre-Bonet
    Applied Health Economics and Health Policy, 2018, 16 : 515 - 525
12345